FDA meeting on epinephrine
This article was originally published in The Tan Sheet
Executive Summary
FDA announces a Dec. 5 public meeting to solicit comments on a proposed rule to amend the agency's regulation on the use of ozone-depleting substances in self-pressurized containers to "remove the essential-use designation for oral pressurized metered-dose inhalers containing epinephrine." In addition, the comment period on the proposed rule published in September is being extended to Dec. 19, FDA says (1"The Tan Sheet" Sept. 24, 2007, p. 7). Meeting attendees must register by Nov. 23, according to the agency...
You may also be interested in...
Primatene Mist To Be Unavailable After 2010 – Proposed Rule
Wyeth will allow its epinephrine-containing Primatene Mist metered-dose inhaler to be phased out of the market after 2010, rather than reformulating to comply with an FDA proposed rule published in the Sept. 20 Federal Register
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.